Research Analysts Set Expectations for CMPS Q1 Earnings

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 EPS estimates for COMPASS Pathways in a note issued to investors on Tuesday, July 15th. HC Wainwright analyst P. Trucchio expects that the company will earn ($0.38) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $45.00 target price on the stock. The consensus estimate for COMPASS Pathways' current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for COMPASS Pathways' Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.41) EPS and Q4 2026 earnings at ($0.43) EPS.

CMPS has been the subject of several other reports. Evercore ISI restated an "in-line" rating and set a $6.00 price objective (down from $11.00) on shares of COMPASS Pathways in a research report on Monday, June 23rd. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $12.00 target price on shares of COMPASS Pathways in a research note on Tuesday, May 27th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, COMPASS Pathways has a consensus rating of "Moderate Buy" and a consensus target price of $17.00.

COMPASS Pathways Trading Up 3.2%

COMPASS Pathways stock traded up $0.13 during midday trading on Wednesday, hitting $4.01. 1,075,818 shares of the stock were exchanged, compared to its average volume of 1,775,243. COMPASS Pathways has a fifty-two week low of $2.25 and a fifty-two week high of $8.54. The stock has a market capitalization of $374.71 million, a price-to-earnings ratio of -2.01 and a beta of 2.12. The stock's 50-day simple moving average is $3.94 and its 200 day simple moving average is $3.77. The company has a current ratio of 10.18, a quick ratio of 10.18 and a debt-to-equity ratio of 0.11.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.03.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Virtus ETF Advisers LLC boosted its stake in shares of COMPASS Pathways by 21.4% in the fourth quarter. Virtus ETF Advisers LLC now owns 16,121 shares of the company's stock valued at $61,000 after purchasing an additional 2,840 shares during the period. Flagship Harbor Advisors LLC boosted its stake in shares of COMPASS Pathways by 27.7% in the first quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company's stock valued at $41,000 after purchasing an additional 3,134 shares during the period. GAMMA Investing LLC boosted its stake in shares of COMPASS Pathways by 93.6% in the first quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock valued at $30,000 after purchasing an additional 5,003 shares during the period. Kennedy Capital Management LLC lifted its stake in COMPASS Pathways by 22.8% in the fourth quarter. Kennedy Capital Management LLC now owns 33,976 shares of the company's stock worth $128,000 after acquiring an additional 6,297 shares during the last quarter. Finally, Barclays PLC lifted its stake in COMPASS Pathways by 2.1% in the fourth quarter. Barclays PLC now owns 419,194 shares of the company's stock worth $1,585,000 after acquiring an additional 8,718 shares during the last quarter. Hedge funds and other institutional investors own 46.19% of the company's stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.